ライフサイエンスコーパス: therapeutics

1 a realistic approach for assessing potential therapeutics.

2 h are utilized in delivery platforms for RNA therapeutics.

3 able tool for testing potential vaccines and therapeutics.

4 sidered when assessing clinical variants and therapeutics.

5 olecular determinants for effective targeted therapeutics.

6 the development and refinement of tau-based therapeutics.

7 which tumor cells evolve, adapt, and resist therapeutics.

8 new peptide for the delivery of nucleic acid therapeutics.

9 he development of novel and effective cancer therapeutics.

10 ents to benefit from advancements in genetic therapeutics.

11 e important insight to both pathobiology and therapeutics.

12 ble platform for intra-articular delivery of therapeutics.

13 pharmaceutical ingredients of approved human therapeutics.

14 is and provides a platform for testing novel therapeutics.

15 BRB/BBB models and novel EC barrier-inducing therapeutics.

16 CG in BTCs and may be tested as a target for therapeutics.

17 ent of efficient, combinatorial gene-editing therapeutics.

18 d for the accelerated discovery of antiviral therapeutics.

19 t in the development of directed RNA editing therapeutics.

20 k will inform the design of future IgA-based therapeutics.

21 rity of CHIKV disease, there are no licensed therapeutics.

22 opes on other Ags and the design of improved therapeutics.

23 usly been explored as a potential anti-Abeta therapeutics.

24 ; enhancing our ability to develop effective therapeutics.

25 ike proliferation in the face of anti-cancer therapeutics.

26 and to applications in the discovery of new therapeutics.

27 e development and testing of clinical cancer therapeutics.

28 patients does not respond to currently used therapeutics.

29 mmation is critical for development of novel therapeutics.

30 h foundation for developing novel intestinal therapeutics.

31 ve immune system and empower diagnostics and therapeutics.

32 eneration of ex vivo derived immune cellular therapeutics.

33 ance for developing and testing vaccines and therapeutics.

34 g it an appealing target for advancing novel therapeutics.

35 ll guide the design of COVID-19 vaccines and therapeutics.

36 ection in the evaluation of future influenza therapeutics.

37 cent advances in the use of cells to deliver therapeutics.

38 d may present as a future target for obesity therapeutics.

39 g biomarker for emerging macrophage-targeted therapeutics.

40 orm preclinical in vivo studies of potential therapeutics.

41 pathways are required to complement existing therapeutics.

42 broadly neutralizing antibodies (bnAbs), and therapeutics.

43 ons in complement research, diagnostics, and therapeutics.

44 rational design of general microbiota-based therapeutics.

45 e for future functional studies and targeted therapeutics.

46 ty, easy accessibility and lack of effective therapeutics.

47 dation for the development of aGPCR-targeted therapeutics.

48 of preclinical evaluations for potential DMD therapeutics.

49 hallenging to develop targeted and selective therapeutics.

50 RNAs (miRNAs) offers a new avenue for cancer therapeutics.

51 o enhance the physical properties of peptide therapeutics.

52 expedite bench-to-bedside translation of new therapeutics.

53 of IFNs, suggesting the potential of IFNs as therapeutics.

54 proteinuric kidney disease and to test novel therapeutics.

55 e of ERK5 and the effectiveness of anti-ERK5 therapeutics.

56 ny disease agents, antibodies can be used as therapeutics.

57 BB and facilitate delivery of targeted brain therapeutics.

58 ing studies to other ABD variants to develop therapeutics.

59 n diagnostic agent for future CAIX-targeting therapeutics.

60 rug screening to identify candidate COVID-19 therapeutics.

61 receptors and discuss potential relevance to therapeutics.

62 nd may guide the development of vaccines and therapeutics.

63 ble models for studying diseases and testing therapeutics.

64 et pharmacodynamic readouts for HTT lowering therapeutics.

65 molecules that hold promise as novel peptide therapeutics.

66 to fast-track development of next-generation therapeutics.

67 signaling targets to consider for precision therapeutics.

68 CoV-2 to aid rational design of vaccines and therapeutics.

69 acilitate development of microbiota-directed therapeutics.

70 fficacy of anti-inflammatory and anti-cancer therapeutics.

71 cell survival and resistance to AR targeting therapeutics.

72 evaluate proposed COVID-19 immunomodulating therapeutics.

73 ant MCMs to assess novel stem cell-based HIV therapeutics.

74 nd in the use of immune checkpoint inhibitor therapeutics.

75 ve strategy for patients receiving Treg cell therapeutics.

76 lth status of patients and their response to therapeutics.

77 nd outcomes have improved little with modern therapeutics.

78 e important for their efficacy and safety as therapeutics.

79 dicating its utility for evaluation of novel therapeutics.

80 ly experience delayed access to unaffordable therapeutics.

81 Our findings may open a new gate toward therapeutics.

82 in consumer products, chemical processes and therapeutics.

83 into the categories of imaging, sensing, and therapeutics.

84 cluding glycan-based biomarker discovery and therapeutics.

85 f unique tools with the potential for future therapeutics.

86 velopment of innovative 'outside of the box' therapeutics.

87 or the development of effective vaccines and therapeutics.

88 ancer represents a major milestone in cancer therapeutics.

89 ng mechanisms, and to design future antibody therapeutics.

90 he major developments in the field of ocular therapeutics.

91 would provide targets for the development of therapeutics.

92 mplications for biochemical research and for therapeutics.

93 e as environmental sentinels or guide living therapeutics.

94 nals for self-powered health diagnostics and therapeutics.

95 t a vulnerable target for the development of therapeutics.

96 ry costs, and faster delivery of appropriate therapeutics.

97 neuronal necrosis represents a target for AD therapeutics.

98 may prove a useful target for new depression therapeutics.

99 ementation of nanomaterials as antimicrobial therapeutics.

100 ready provided important insights into these therapeutics.

101 multidrug resistance by exporting different therapeutics across cell membranes, often by utilizing t

102 sents a promising approach to developing RAS therapeutics against a broad array of cancers.

103 ping disorders and investigated as potential therapeutics against cocaine addiction and for cognitive

104 A2 in mucus hypersecretion may lead to novel therapeutics against excessive mucus in both human and v

105 for the development of improved vaccines and therapeutics against IBVs.

106 clic nitroimidazole scaffolds as a source of therapeutics against infectious diseases.

107 entify new targets for improved vaccines and therapeutics against influenza and one such target is th

108 There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent

109 significance in Asia, vaccines and specific therapeutics against SFTS are still unavailable.

110 strategic clues for the development of novel therapeutics against this rapidly emerging worldwide cri

111 Our work implies that novel therapeutics aimed at improving vascular mitochondrial b

112 Here we discuss emerging therapeutics aimed at prevention and treatment of AMR.

113 knowledge opens the door for potential novel therapeutics aimed at shaping a less dysbiotic microbiom

114 cal community due to their promise for human therapeutics and an alternative to chemotherapy for canc

115 -binding domain (RBD) are being developed as therapeutics and are a major contributor to neutralizing

116 ays, which opens new venues for establishing therapeutics and biomarkers at the protein and RNA level

117 ides a roadmap for the development of future therapeutics and demonstrates the transformative potenti

118 idates, as well as developing antibody-based therapeutics and diagnostics for CoV-2.

119 d permit the targeted delivery of NANP-based therapeutics and diagnostics.

120 ll aid development of refined AMPAR epilepsy therapeutics and facilitate to uncover the mechanisms by

121 rational development of new brain-penetrant therapeutics and for advancing understanding of brain va

122 bose) polymerase (PARP) inhibitors and other therapeutics and for the development of new treatments.

123 g mechanisms of function and engineering new therapeutics and nanotechnologies.

124 eveloped to overcome the limitations of free therapeutics and navigate biological barriers - systemic

125 l solid organ transplants, there are limited therapeutics and patient-specific diagnostics currently

126 hrough this, we emphasize recent advances in therapeutics and pinpoint disease-associated variants th

127 about combination therapy using conventional therapeutics and repurposed drugs or phytochemicals for

128 ogens has led to severe deficit of available therapeutics and requires novel interventions.

129 DRmiRs) enhanced the response to anti-cancer therapeutics and resulted in effective cell death.

130 tau (p-tau) to identify potential tauopathy therapeutics and risk factors.

131 ebacase and direct lytic agents as potential therapeutics and supports conduct of a confirmatory stud

132 odulation of gene expression using small RNA therapeutics and the improvement of precise gene editing

133 odel of hyperaldosteronism to investigate PA therapeutics and the mechanisms leading to the damaging

134 ficant advancements have been made in cancer therapeutics and treatments, early disease detection and

135 sociated developments in systems immunology, therapeutics and vaccine design should be at the heart o

136 agents is relevant to the development of new therapeutics and vaccines.

137 hat may facilitate development of SARS-CoV-2 therapeutics and vaccines.

138 clinical diagnosis, facilitated discovery of therapeutics, and begun to enable investigation of virul

139 unodeficiency virus type 1 (HIV-1) vaccines, therapeutics, and cure strategies.

140 ease models (e.g. stroke), vascular-targeted therapeutics, and hemodynamic data from other imaging mo

141 siveness of some cancers, development of mAb therapeutics, and the etiology of a congenital glycosyla

142 mode of action for HU and identify potential therapeutics: annexin V and anti-ICAM-1 antibodies.

143 RNA therapeutics are a promising strategy to treat genetic d

144 e of early-onset dementia, is available, but therapeutics are being investigated to target the 2 main

145 diverse NK cell products and their auxiliary therapeutics are being leveraged to target human cancers

146 New therapeutics are critically needed to counter the source

147 The vast majority of therapeutics are directed solely at neurons, despite the

148 RNA therapeutics are finally taking their place as a main dr

149 andemic are prophylactic vaccines, antiviral therapeutics are important to limit morbidity and mortal

150 nterovirus 71, and specific anti-enterovirus therapeutics are lacking.

151 Targeted therapeutics are needed for triple-negative breast cance

152 nditions in developed nations, yet effective therapeutics are not identified for many of them.

153 f the adverse effects associated with opioid therapeutics are realized after extended dosing.

154 or the first time that small-molecule cancer therapeutics are selectively partitioned and concentrate

155 Various vaccines and therapeutics are under development and expected to be av

156 New therapeutics are urgently needed to treat this infection

157 Platinum-based therapeutics are used to manage many forms of cancer, bu

158 ies (mAb) with the potency of small molecule therapeutics, are one of the fastest growing pharmaceuti

159 ently, there are no FDA-approved vaccines or therapeutics available to combat VEEV infection.

160 e, our aim was to develop novel antifibrotic therapeutics based on naturally derived substance librar

161 nities is imperative to expand the available therapeutics beyond anticoagulants and to target both th

162 proved peanut OIT product Palforzia (Aimmune Therapeutics, Brisbane, Calif).

163 cal lead for the development of C. difficile therapeutics but also highlights dramatic drug potency e

164 omoting heterochromatin are potential cancer therapeutics but very few are known.

165 Antibodies are widely used as cancer therapeutics, but their current use is limited by the lo

166 by reporting how MIPs themselves can act as therapeutics by inhibiting cancer growth.

167 Ideal therapeutics candidates for this mode of delivery are th

168 and the Critical Path Institute's Transplant Therapeutics Consortium convened a public workshop title

169 Advancement of near-term targeted therapeutics could crucially depend on thoughtful design

170 t of targeted and immune checkpoint blocking therapeutics, current strategies have limited success in

171 As with other types of therapeutics, delivery vehicles for nucleic acids must a

172 lopment of polypeptide conjugates to advance therapeutics, diagnostics, and fundamental science.

173 , with an emphasis on the delivery of CRISPR therapeutics directly into the human body using adeno-as

174 In contrast with previous therapeutics directly linking Dox and TF, cytotoxicity o

175 est that these molecules may serve as useful therapeutics during coronavirus outbreaks.

176 nt for targeted central nervous system (CNS) therapeutics, especially with carboxylic acid-containing

177 Current monoamine transmission modulating therapeutics, even with proper adherence and acceptable

178 ogy, risk prediction, and development of new therapeutics for AF.

179 nstream targets for the development of novel therapeutics for bipolar mania.

180 Targeted therapeutics for cancer generally exploit "oncogene addi

181 targets for the development of experimental therapeutics for cancer, metabolic, and immunological di

182 opment of oncolytic VSV recombinants as safe therapeutics for cancer.

183 ultimately facilitate the development of new therapeutics for cardiovascular diseases.

184 insights into the future of microbiota-based therapeutics for CDI.

185 oV-2, such that the repurposing of anti-IL-6 therapeutics for COVID-19 is now a major line of investi

186 , and reproducible platforms to screen novel therapeutics for CRS.

187 ology of chronic cachexia and a tool to test therapeutics for disease reversal.

188 (GRKs) are attractive targets for developing therapeutics for heart failure.

189 In pursuit of therapeutics for human polyomaviruses, we identified a p

190 pavirus outbreaks, licensure of vaccines and therapeutics for human use will likely require demonstra

191 chnique may contribute to the development of therapeutics for hypoxia/inflammatory-related diseases.

192 This review provides an overview of EV-based therapeutics for I-R injury in kidneys, liver, heart, lu

193 The identification of targeted therapeutics for individuals carrying mutations in these

194 Despite attempts to develop tolerable therapeutics for management of AMR, none, to date, have

195 e development of conditional diagnostics and therapeutics for multiple cancer types.

196 arkable process may help the design of novel therapeutics for neurodegeneration and other pathologies

197 e emerged as a class of potentially powerful therapeutics for neurodegenerative CNS diseases.

198 ation of Biomarkers to Develop Non-Addictive Therapeutics for Pain workshop convened scientific leade

199 or developing strategies to deliver emerging therapeutics for peritoneal cancer treatment using nanoc

200 IgE production is required to develop better therapeutics for preventing this severe reaction.

201 ll facilitate progress in the development of therapeutics for RBD and associated neurodegenerative di

202 urther studying fetal outcomes and potential therapeutics for the prevention of inflammation-induced

203 loration of potential oral, once-a-day PCSK9 therapeutics for the treatment of cardiovascular disease

204 nts may potentially be translated into novel therapeutics for the treatment of COPD.

205 gulated may present an opportunity to refine therapeutics for the treatment of pain.

206 Bispecific antibody-based therapeutics for the treatment of TNBC have gained recen

207 ising avenue to follow in the development of therapeutics for treatment of S. pneumoniae.

208 In the absence of approved vaccines and therapeutics for use in humans, Nipah virus (NiV) contin

209 Development of tendon therapeutics has been hindered by the lack of informativ

210 he renaissance of complement diagnostics and therapeutics has introduced precision medicine into a wi

211 These therapeutics have been shown to cure some patients with

212 d controlled trials, most of these potential therapeutics have been studied in animals.

213 Novel therapeutics have largely failed to translate from promi

214 Countless promising therapeutics have shown efficacy in rodent Alzheimer's d

215 Microbiome-modulating therapeutics have the potential to revolutionize medicin

216 No therapeutics have yet been proven effective for the trea

217 These results suggest that sleep therapeutics immediately following trauma exposure may b

218 ould be considered to supplement current HIV therapeutics.IMPORTANCE Oregano essential oil has multip

219 et effects of both established and candidate therapeutics in a mouse model of autism spectrum disorde

220 rogel provides flexibility for encapsulating therapeutics in a reversible and conforming system for l

221 n pursued for the development of anti-cancer therapeutics in combination with ionizing radiation (IR)

222 ent upon the development of pathway-specific therapeutics in conjunction with biomarkers that predict

223 p53 for cancer therapy, but also to peptide therapeutics in general aimed at targeting intracellular

224 on of this class of promising anti-microbial therapeutics in heterologous systems.

225 therapeutic rationale behind B-cell-directed therapeutics in MS, and proposes strategies to optimize

226 of these repeats occurs has implications for therapeutics in multiple diseases.

227 This new approach might lead to precision therapeutics in patients with cancer.

228 cal and clinical trials that have tested ASO therapeutics in polyQ disorders.

229 t of protein replacement and gene correction therapeutics in targeted tissues.

230 ay lead to the development of glyco-specific therapeutics in the treatment of cardiovascular disease.

231 lenges associated with administering protein therapeutics, including biotransformation via clipping,

232 ML cells express low levels of TNTs, but CML therapeutics increase TNT formation in designated cell m

233 rated a crucial gap of knowledge, leading to therapeutics indiscriminately blocking IL-17A and global

234 the framework for optimization in cell-based therapeutics intended to mitigate cardiomyopathic damage

235 ct assembly of the subunits in this class of therapeutics is a critical quality attribute (CQA) with

236 ring challenge to develop controlled release therapeutics is appraised, with commentary on current su

237 Included in this class of therapeutics is enfuvirtide, a 36-residue peptide drug t

238 , because metabolic adaptation to anticancer therapeutics is rooted in this inherent metabolic plasti

239 and development of monoclonal antibody (mAb) therapeutics is the determination of heavy chain and lig

240 potential nutritional, immune, and microbial therapeutics may be developed into promising future aven

241 hese results indicate that MARCKS ED peptide therapeutics may overcome traditional GBM resistance mec

242 pathogenesis that is impeding development of therapeutics.METHODSUsing multiplex immunohistochemistry

243 evelopment of highly effective CFTR-directed therapeutics, now applicable for up to 90% of people wit

244 re an indispensable class of drugs and often therapeutics of last resort.

245 could utilize this technology for vaccines, therapeutics or other biopharmaceuticals that are not co

246 reverse the DNA modification by anti-cancer therapeutics or trans-membrane efflux proteins that pump

247 Without approved antiviral therapeutics or vaccines to this ongoing global threat,

248 mbrane efflux proteins that pump anti-cancer therapeutics out of the cytosol.

249 We report a proximity-enabled reactive therapeutics (PERx) approach to generate covalent protei

250 or fields including biophysics, diagnostics, therapeutics, photonics, and nanofabrication.

251 g of the mechanism of gymnotic uptake of RNA therapeutics remains limited by the methods commonly use

252 rapy, but the efficacy of these breakthrough therapeutics remains limited, as many patients fail to r

253 tion of signaling kinetics to developing new therapeutics requires reliable kinetic assays and an ana

254 Despite the urgent need to find effective therapeutics, research on SARS-CoV-2 has been affected b

255 PS-modified nucleic acid therapeutics show improved metabolic stability from nucl

256 In this Review, we highlight I/R-targeting therapeutics shown to improve microvascular blood flow i

257 Most current therapeutics suffer from widespread resistance, creating

258 ion and clearance and to screen and evaluate therapeutics targeting alpha-syn aggregation and LB form

259 New therapeutics targeting immune checkpoint proteins have s

260 y actually suffer from a mixed dementia, and therapeutics targeting only Alzheimer's disease-related

261 s for Rho-family small GTPase inhibitors and therapeutics targeting Ras-driven cancers.

262 ould facilitate the development of antiviral therapeutics targeting the CHIKV attachment step.

263 d DR, there is an urgent need to develop new therapeutics targeting the mitochondria to prevent or re

264 gress to date in the clinical development of therapeutics targeting the Notch, WNT, Hedgehog and Hipp

265 a bright future for targeted small molecule therapeutics that affect RNA function.

266 This review focuses on therapeutics that aim to modulate the gut microbiota and

267 by variable domain sequence - returning all therapeutics that are within a specified sequence identi

268 agments to enhance the capabilities of human therapeutics that benefit from target clustering and hig

269 in addition to the broadening set of cancer therapeutics that can induce prolongation of the correct

270 opment of prebiotic, probiotic, or synthetic therapeutics that decrease the risk of autoimmune, metab

271 eal a mechanism of action for fumarate-based therapeutics that include DMF, for the treatment of mult

272 p in the design of effective and alternative therapeutics that may disassociate the synergistic or ad

273 Therapeutics that restore healthy mitochondrial function

274 eases and to inform the development of novel therapeutics that target deleterious glial activity.

275 Therapeutics that target the T cell inhibitory checkpoin

276 elsus (1493-1541) on chemical agents used as therapeutics, "the dose makes the poison," it is now rea

277 n to outperform conventional diagnostics and therapeutics, thereby facilitating their clinical applic

278 There are currently no therapeutics to address this due to lack of insight into

279 tiate endogenous 5-HT tone may provide novel therapeutics to alleviate the impact of costly, chronic

280 oactive compounds allow targeted delivery of therapeutics to cell types of choice based on that antib

281 will contribute to the development of novel therapeutics to combat early infection.

282 -NPs to unleash the potential of brain tumor therapeutics to improve their treatment efficacy.

283 in cancers, making it a potential target for therapeutics to limit the progression of these diseases.

284 an attractive target for the development of therapeutics to manage various B cell and T cell tumors,

285 a potential non-invasive means of delivering therapeutics to patients.

286 or (kappaOR) is an important target for pain therapeutics to reduce depression and other harmful side

287 (BBB) is a major obstacle to the delivery of therapeutics to the brain.

288 ave potential utility for the development of therapeutics to treat diabetes and obesity-associated di

289 hat could be exploited in the development of therapeutics to treat obstructive lung diseases.

290 lization, are proving to effectively deliver therapeutics to tumours.

291 Current therapeutics typically involve partially relieving the h

292 wing treatment with the highly effective CML therapeutics tyrosine kinase inhibitors (TKIs) and inter

293 Here, we review all the therapeutics used during MP in different organ systems (

294 ns around how to achieve optimal delivery of therapeutics via BBB disruption.

295 In an effort to develop new HAT therapeutics, we report the structure-activity relations

296 there is an increasing push for personalized therapeutics, where plans for medical care are establish

297 se that measure total cellular uptake of RNA therapeutics, which includes both productive and non-pro

298 itability of models for testing vaccines and therapeutics, which may evolve as our understanding of C

299 hat could provide new options for cell-based therapeutics with curative intent.

300 e of the fastest growing classes of oncology therapeutics, with eight ADCs and two immunotoxins appro